Multicentre randomized clinical trial to investigate the cost-effectiveness of an allogeneic single-donor fibrin sealant after coronary artery bypass grafting (FIBER Study)

British Journal of Surgery

Volumn 102, Issue 11, 2015, Pages 1338-1347

  Tavilla, G ^a   Bruggemans, E F ^a   Gielen, C L I ^a   Brand, A ^b   Van Den Hout, W B ^a   Klautz, R J M ^a   Van Hilten, J A ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN GLUE; HEMOSTATIC AGENT;

ADULT; AGED; BLOOD LOSS, SURGICAL; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST BENEFIT ANALYSIS; ECONOMICS; ELECTIVE SURGERY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOSTASIS; HOSPITAL COST; HUMAN; INTENSIVE CARE; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; PLASMA; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; THROMBOCYTE TRANSFUSION; UTILIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD LOSS, SURGICAL; CORONARY ARTERY BYPASS; COST-BENEFIT ANALYSIS; CRITICAL CARE; ELECTIVE SURGICAL PROCEDURES; ERYTHROCYTE TRANSFUSION; FEMALE; FIBRIN TISSUE ADHESIVE; HEMOSTASIS, SURGICAL; HEMOSTATICS; HOSPITAL COSTS; HUMANS; INTENTION TO TREAT ANALYSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; NETHERLANDS; PLASMA; PLATELET TRANSFUSION;

EID: 84941172709     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9877     Document Type: Article

References (33)

1. Paone G, Likosky DS, Brewer R, Theurer PF, Bell GF, Cogan CM, et al. Transfusion of 1 and 2 units of red blood cells is associated with increased morbidity and mortality. Ann Thorac Surg 2014; 97: 87-93.
2. Engoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ,. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 2002; 4: 1180-1186.
3. LaPar DJ, Crosby IK, Ailawadi G, Ad N, Choi E, Spiess BD, et al. Blood product conservation is associated with improved outcomes and reduced costs after cardiac surgery. J Thorac Cardiovasc Surg 2013; 145: 796-804.
4. Spotnitz WD, Burks S,. State-of-the-art review: hemostats, sealants, and adhesives II: update as well as how and when to use the components of the surgical toolbox. Clin Appl Thromb Hemost 2010; 16: 497-514.
5. Albala DM, Lawson JH,. Recent clinical and investigational applications of fibrin sealant in selected surgical specialties. J Am Coll Surg 2006; 4: 685-697.
6. Mangano DT, Tudor IC, Dietzel C,; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-365.
7. Buchta C, Hedrich HC, Macher M, Höcker P, Redl H,. Biochemical characterization of autologous fibrin sealants produced by Cryoseal® and Vivostat® in comparison to the homologous fibrin sealant product Tissucol/Tisseel®. Biomaterials 2005; 26: 6233-6241.
8. Lytle BW, Blackstone EH, Sabik JF, Houghtaling P, Loop FD, Cosgrove DM,. The effect of bilateral internal thoracic artery grafting on survival during 20 postoperative years. Ann Thorac Surg 2004; 78: 2005-2012.
9. Kurlansky PA, Traad EA, Dorman MJ, Galbut DL, Zucker M, Ebra G,. Thirty-year follow-up defines survival benefit for second internal mammary artery in propensity-matched groups. Ann Thorac Surg 2010; 90: 101-108.
10. Tuman KJ, McCarthy RJ, O'Connor CJ, McCarthy WE, Ivankovich AD,. Aspirin does not increase allogeneic blood transfusion in reoperative coronary artery surgery. Anesth Analg 1996; 83: 1178-1184.
11. Gansera B, Schmidtler F, Gillrath G, Angelis I, Wenke K, Weingartner J, et al. Does bilateral ITA grafting increase perioperative complications? Outcome of 4462 patients with bilateral versus 4204 patients with single ITA bypass. Eur J Cardiothorac Surg 2006; 30: 318-323.
12. Hazelaar S, Dijkstra-Tiekstra MJ, Korte de D, Wildt de-Eggen J,. Allogenic single-donor CryoSeal produced from fresh-frozen quarantine apheresis plasma as alternative for multidonor or autologous fibrin sealants. Transfusion 2012; 52: 517-523.
13. American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology 2006; 105: 198-208.
14. Dutch Institute for Healthcare Improvement (CBO). Blood Transfusion Guideline [CBO-richtlijn bloedtransfusies]. Van Zuiden Communications: Alphen aan den Rijn, 2004.
15. Schultz KF, Grimes DA,. Multiplicity in randomised trials II: subgroup and interim analyses. Lancet 2005; 365: 1657-1661.
16. Choi JC, Bakaeen FG, Cornwell LD, Dao TK, Coselli JS, LeMaire SA, et al. Morbid obesity is associated with increased resource utilization in coronary artery bypass grafting. Ann Thorac Surg 2012; 94: 23-28.
17. Hakkaart-van Roijen L, Tan S, Bouwmans C,. Manual for Costing: Methods and Standard Costs for Economic Evaluations in Healthcare [Handleiding voor kostenonderzoek: methoden en standard kostprijzen voor economische evaluaties in de gezondheidszorg]. Health Care Assurance Board: Diemen, 2010.
18. Sanquin Board of Directors. Price List Products and Services of Sanquin Blood Supply [Prijslijst Producten en Diensten Sanquin Bloedvoorziening]. Sanquin Blood Supply: Amsterdam, 2012.
19. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR,. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion 2010; 50: 753-765.
20. Zethraeus N, Johannesson M, Jonsson B, Löthgren M, Tambour M,. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies. Pharmacoeconomics 2003; 21: 39-48.
21. Andreasen JJ, Westen M, Pallesen PA, Jensen S, Gorst-Rasmussen A, Johnsen SP,. Transfusion practice in coronary artery bypass surgery in Denmark: a multicentre audit. Interact Cardiovasc Thorac Surg 2007; 6: 623-627.
22. Daly DY, Myles PS, Smith JA, Knight JL, Clavisi O, Bain DL, et al. Anticoagulation, bleeding and blood transfusion practice in Australasian cardiac surgical practice. Anaesth Intensive Care 2007; 35: 760-768.
23. Koch CG, Li L, Duncan AI, Mihalijevic T, Cosgrove DM, Loop FD, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 2006; 34: 1608-1616.
24. Arora RC, Légaré JF, Buth KJ, Sullivan JA, Hirsch GM,. Identifying patients at risk of intraoperative and postoperative transfusion in isolated CABG: toward selective conservation strategies. Ann Thorac Surg 2004; 78: 1547-1555.
25. Shevde K, Pagala M, Kashikar A, Tyagaraj C, Shahbaz N, Iqbal M, et al. Gender is an essential determinant of blood transfusion in patients undergoing coronary artery bypass graft procedure. J Clin Anesth 2000; 12: 109-116.
26. Woodman RC, Harker LA,. Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76: 1680-1697.
27. Knudsen L, Hasenkam JM, Kure HH, Hughes P, Bellaiche L, Ahlburg P, et al. Monitoring thrombin generation with prothrombin fragment 1, 2 assay during cardiopulmonary bypass surgery. Thromb Res 1996; 84: 45-54.
28. Kjaergard HK, Fairbrother JE,. Controlled clinical studies of fibrin sealant in cardiothoracic surgery-a review. Eur J Cardiothorac Surg 1996; 10: 727-733.
29. Lamm P, Adelhard K, Juchem G, Weitkunat R, Milz S, Kilger E, et al. Fibrin glue in coronary artery bypass grafting operations: casting out the Devil with Beelzebub. Eur J Cardiothorac Surg 2007; 32: 567-572.
30. Goerler H, Oppelt P, Abel U, Haverich A,. Safety of the use of Tissucol Duo S in cardiovascular surgery: retrospective analysis of 2149 patients after coronary artery bypass grafting. Eur J Cardiothorac Surg 2007; 32: 560-566.
31. Sellman M, Intonti MA, Ivert T,. Reoperations for bleeding after coronary artery bypass procedures during 25 years. Eur J Cardiothorac Surg 1997; 11: 521-527.
32. Rousou JA,. Use of fibrin sealants in cardiovascular surgery: a systematic review. J Card Surg 2013; 28: 238-247.
33. Järvinen TL, Sievänen H, Kannus P, Jokihaara J, Khan KM,. The true cost of pharmacological disease prevention. BMJ 2011; 342: d2175.